AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01171508 — intervention group
Intervention type: DEVICE
Intervention: Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA
Description: Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
Study NCT01171508 — intervention group
Intervention type: DEVICE
Intervention: Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)
Description: Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
Study NCT01171508 — intervention group
Intervention type: DEVICE
Intervention: Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)
Description: Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
Study NCT01171508 — intervention group
Intervention type: PROCEDURE
Intervention: Urine 6-sulphatoxymelatonin (aMT6s)
Description: Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
Study NCT01171508 — intervention group
Intervention type: OTHER
Intervention: Karolinska Sleepiness Scale
Description: Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
Study NCT01171508 — intervention group
Intervention type: OTHER
Intervention: Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain
Description: Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
Study NCT01171508 — intervention group
Intervention type: OTHER
Intervention: Sleep-diary
Description: Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
Study NCT03437057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (below or equal to) 250 mg
Description: Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
Study NCT03847636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CryoBalloon ablation
Description: Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
Study NCT01376882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
Study NCT01032590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet weight loss intervention
Description: Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
Study NCT01032590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet weight loss intervention
Description: Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
Study NCT00627731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate (mPSL)
Description: mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
Study NCT00627731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone (PSL)
Description: PSL 40 mg per day for 10 days
Study NCT01155531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline plus Telenzepine
Description: oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
Study NCT00218244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Nicotine Smokeless Tobacco Product
Description: Skoal for 50% reduction;Skoal bandits for 75% reduction.
Study NCT00218244 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Counseling
Description: Behavioral counseling alone for reduction in tobacco use.
Study NCT01776099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement (4 arms, 2 active, 2 placebo)
Study NCT01776099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement (4 arms, 2 active, 2 placebo)
Study NCT02563184 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Study NCT02196181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02196181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT02196181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO
Study NCT02196181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT02196181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT02196181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT02196181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT01854567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of one MPC expanded cord unit and one unexpanded cord unit
Description: Infusion of one MPC expanded cord unit and one unexpanded cord unit.
Study NCT01854567 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of two unexpanded cord blood units.
Description: Umbilical Cord Blood.
Study NCT02138578 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Study NCT02138578 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study NCT03867474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
Study NCT03870633 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo medical chart abstraction
Study NCT03870633 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Complete telephone interview
Study NCT03870633 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Ancillary studies
Study NCT03870633 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03078543 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ANTHEM™ PS Total Knee System implant
Description: The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~* Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~* Titanium primary tibial components~* Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~* Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications.
Study NCT00001230 — intervention group
Intervention type: DRUG
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine is a drug administered under an IND held by the CDC. Standard dosing is used.
Study NCT03830151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT03830151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study NCT02138578 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Study NCT04590729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-min Exercise Per 30 Min
Description: This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
Study NCT04590729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-min Exercise Per 15 Min
Description: This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
Study NCT03331172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
Study NCT04569825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ophtamesone
Description: local application intranasally as drops
Study NCT04569825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ophtamesone
Description: local application intranasally as drops
Study NCT03150641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord clamping
Description: The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
Study NCT03150641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Umbilical cord clamping
Description: The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
Study NCT02629809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02629809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT02629809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02629809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT01628809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: three-day mindfulness-based meditation retreat program
Study NCT00089128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00089128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT02088944 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Study NCT02232646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
Study NCT01628809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: three-day mindfulness-based meditation retreat program
Study NCT03733483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
Study NCT02955550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-2
Description: Human recombinant Interleukin-2
Study NCT02955550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNK-007
Description: PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
Study NCT00625729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Day 0-14, 10 million international units, 3 times per week for 6 doses
Study NCT00625729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic natural killer cells
Description: Day 0 infusion of cells (1.5-8 x 10\^7 cells/kg).
Study NCT04481009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 60 minutes every 21-day cycle.
Study NCT04481009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with fixed dose of 240 mg administered intravenously followed by YH003 administered intravenously every 21-day cycle.
Study NCT00625729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m\^2
Study NCT00625729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg intravenous (IV) on Day -5.
Study NCT01765647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGY
Description: AGY is a natural health product produced in egg yolks
Study NCT03531372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mipolixin®
Description: 1.55g chewable tablet 5 times a day for 2 weeks
Study NCT03531372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Poliprotect®
Description: 1.55 g chewable tablet 5 times a day for 2 weeks
Study NCT01744899 — intervention group
Intervention type: OTHER
Intervention: Sitting posture
Description: The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
Study NCT01721369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transient Loss of Consciousness (T-LOC)
Study NCT01346137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: 15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
Study NCT04459910 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair
Description: After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
Study NCT03348631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03348631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03348631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study NCT00695994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
Study NCT00695994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and carboplatin
Description: Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
Study NCT04661618 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gym Tonic programme and Gym equipment
Description: 12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
Study NCT04661618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gym Tonic programme and Gym equipment
Description: 12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
Study NCT00625729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
Study NCT01927861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
Study NCT03325803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study NCT04481009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered each 21-day cycle.
Study NCT04481009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administrated each 21-day cycle.
Study NCT04587180 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopic suture-bridge rotator cuff repair
Description: Arthroscopic suture-bridge repair is a widely used and universal surgical method for symptomatic rotator cuff tear patients. It is arthroscopic surgery to reattach ruptured rotator cuff tendons to the original insertion (greater tuberosity) using medial and lateral row anchors.
Study NCT05559333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: class I restoration placement
Description: zirconomer, glass carbomer, glass ionomer and composite resin class I restorations were placed.
Study NCT03325803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
Study NCT03325803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Study NCT03325803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurements of the fluorescence intensity
Description: After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.